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Abstract
Like their normal counterparts, many tumours are thought to have a
hierarchical organization, albeit a disorganized one. Accordingly,
the concept of cancer stem cells has emerged, and that these cells
are responsible for perpetuating tumour existence. Operationally,
cancer stem cells are regarded as prospectively purified cells that
are the most effective at tumour initiation in an in vivo assay,
usually after xenotransplantation to NOD/SCID mice. The con-
ventional wisdom is that such tumour-initiating cells are rare based
upon having to xenotransplant large numbers of human tumour
cells into immunodeficient mice to propagate the tumour, but new
evidence indicates that perhaps these cells are not so rare, at least
in malignant melanoma, if a supportive soil is provided for the
transplanted cells along with further restriction of the murine host’s
immune response.
Phenotypic markers of cancer stem cells
The idea that cancers have malignant cancer stem cells
(CSCs) is only now gaining widespread acceptance –
despite the fact that, using colony formation in soft agar as a
surrogate stem cell assay, Hamburger and Salmon found in
1977 that, for many human tumours, only 1 in 1,000 to 1 in
5,000 cells was able to form a macroscopic colony [1].
Selection for many of these putative CSCs is based upon
expression levels of either the ABC superfamily of membrane
transporters [2] or the aldehyde dehydrogenase (ALDH)
gene superfamily encoding detoxifying enzymes for many
pharmaceuticals and environmental pollutants. As such, these
CSCs are typically enriched after conventional treatments to
which they are resistant.
The most popular marker of putative stem cells is seemingly
Prominin-1 (CD133), the first identified member of the rapidly
growing prominin family of pentaspan membrane proteins [3],
with expression restricted to plasma membrane protrusions,
such as epithelial microvilli. CD133 has been used to enrich
for cells with tumour-initiating ability from a variety of human
solid tumours, including the brain, the prostate, the liver, the
breast and the colon [4], although the utility in colon cancer
has been disputed [5].
In breast cancer cell lines, as few as 500 ALDH+ cells can
form tumours in NOD/SCID mice [6]. From primary tumours
that had cells positive not only for the familiar breast CSC
signature (CD44+CD24–) but also for ALDH, as few as 20
cells were tumorigenic; on the other hand, 50,000
CD44+CD24–ALDH– cells were nontumorigenic [7]. Breast
cancers with cells expressing the CD44+CD24– phenotype
are most common in basal-like tumours, but not all breast
cancers contain a subpopulation with this phenotype [8], and
in Brca1-deficient mouse mammary tumours there appear to
be distinct CD44+CD24– and CD133+ subpopulations with
stem cell properties [9] (see Figure 1). Moreover, within a
tumour, cells may acquire stem cell properties through
epithelial–mesenchymal transition (see Figure 1). Transformed
human mammary epithelial cells with ectopic expression of
the transcription factors Twist or Snail undergo epithelial–
mesenchymal transition with loss of E-cadherin and gain of
vimentin; remarkably, almost all of these cells had the
CD44+CD24– phenotype [10].
Cancer stem cells: as rare as hen’s teeth or as
common as muck?
Using the NOD/SCID assay, malignant melanoma initiating
cells have been found to be rare amongst the unsorted
tumour population (~1 in 106) – but they can be enriched to
about 1 in 158,000 when cells are sorted for the likely
melanoma chemoresistance mediator ABCB5, a member of
the ABC transporter family [11]. Optimization of the assay,
however, can drastically improve the tumorigenicity of the
cells down to a level where even single cells can initiate
tumour growth [12]. Using the standard NOD/SCID assay,
limiting dilution assays – whereby between 107 down to 102
unsorted cells were transplanted – suggested that, as
observed before, about 1 in 837,000 cells was a tumour-
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initiating cell (TIC). Palpable tumours appeared earlier and
grew faster when the transplanted cells were supported by
Matrigel; when similarly prepared cells from primary tumours
were transplanted to NOD/SCID Il2rγ–/– mice, one in four
cells was estimated to be a TIC. These recipient mice clearly
represent a more permissive immune microenvironment, in
particular lacking natural killer cell activity. Likewise, 254
single-cell transplantations derived from four patients yielded
69 tumours (a take rate of 27%), again demonstrating a
fantastic improvement in tumorigenicity with this new model.
Refining the cancer stem cell hypothesis: 
not one cap fits all
So is the CSC hypothesis dead or merely in need of
modification? We would argue for the latter. Particularly in
epithelial tissues with ordered structure, such as the
epidermis, there is no doubt that many cells are undergoing
terminal differentiation – in fact, all of the suprabasal cells.
Likewise, in epidermal squamous cell carcinomas – particu-
larly well-differentiated ones – many cells are reproductively
sterile; for example, the cells comprising the pearls of
keratinized squames – clearly less than one in four of these
tumour cells are TICs.
So are malignant melanomas unrepresentative of the majority
of tumours? Perhaps in some respects they are; for example,
metastases typically occur very early in tumour development,
melanomas are one of the few tumours where the isolated
cells are highly resistant to apoptosis (anoikis) [13], and,
with respect to epithelial mesenchymal transition, melano-
cytes developmentally upregulate transcription factors such
as Slug during migration from the neural crest. On the other
hand, melanocytes can divide and are renewed from the hair
follicle bulge region, and are responsive to differentiating
influences [14].
Despite the caveats regarding malignant melanoma, this new
study alerts us to the fact that the NOD/SCID assay merely
identifies cells able to form tumours in a hostile murine
environment, and that many factors conspire to vastly
underestimate the frequency of TICs. These include the
absence of a niche for the transplanted cells (partially
mimicked by Matrigel), and the recipient’s residual immune
system. These assertions are underscored by the fact that as
few as 10 mouse lymphoma or acute myeloid leukaemia cells
can regularly propagate tumours when transplanted into
histocompatible mice [15]. So are all cells in these tumours
possible TICs?
The rarity of cancer stem cells has also been questioned in
mouse mammary cancer. Using up to a dozen murine mammary
cancer cell lines, cell colonies could be regularly generated from
randomly selected single cells; and when 2 x 105 cells from
these clonally derived colonies were allografted into
histocompatible mice, tumours were consistently produced –
suggesting that perhaps the TICs do not have a unique surface
marker signature [16]. On the other hand, cell sorting of
heterogeneous mammary tumour cells from p53-null Balb/c
mice has identified a distinct subset of CD29highCD24highLin–
cells that were highly enriched for TICs when transplanted into
the cleared fat pads of syngeneic wild-type Balb/c mice [17].
Figure 1
Current concepts regarding stem cells and tumour evolution in tissues
with ordered structure. (a) In normal tissue, adult stem cells (ASC)
(yellow) self-renew and give rise to transit amplifying cells (TAC)
(green) that divide several times before undergoing terminal
differentiation (TD) (red). Many lines of evidence, including direct
lineage tracing from genetically marked ASC, indicate that tumours
arise from ASC, although an origin from TAC is also possible.
(b) Tumours also have a hierarchical structure, albeit a relatively
disorganized one. The cancer stem cells (CSCs) (yellow, blue border)
may have a single phenotype and be rare or relatively common.
(c) Genetic or epigenetic events may result in new clones driven by
phenotypically diverse populations of CSCs. (d) Further genetic or
epigenetic changes may result in some cells undergoing
epithelial–mesenchymal transition (EMT), equipping them with CSC
properties. (e) Metastasis may be caused by migrating CSCs
detaching from the tumour mass; in particular, these may be the CSCs
formed through EMT that may respond to chemotactic gradients by
virtue of expression of chemokine receptors such as CXCR4.Limiting dilution transplantation experiments certainly
supported the CSC hypothesis, and the small numbers of
cells transplanted (100 cells) to obtain heterogeneous
tumours indicated that perhaps the TICs were at least
bipotential. The question of whether tumour heterogeneity is
due to distinct clones from different CSCs or whether CSCs,
like their normal counterparts, are multipotential is of
fundamental importance. This question has been answered in
colorectal cancer; clonal populations derived from a
colorectal cancer cell line and from primary colorectal cancer
can subsequently recapitulate the heterogeneity of the
original tumours when transplanted in nude mice, exhibiting
enterocytic, neuroendocrine and goblet cell differentiation –
all from a single cell [18,19].
Conclusions
The CSC hypothesis is not dead, but it needs refining to
accommodate the likelihood that the frequency of CSCs may
vary from tumour to tumour and is likely to change during
tumour progression by both epithelial–mesenchymal
transition as well as by the symmetric cell division of CSCs
themselves.
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